Glycopyrronium Bromide Ethypharm (Glycopyrronium Bromide)

Glycopyrronium Bromide Ethypharm is employed in medical settings where reduction of secretions or smooth‑muscle activity is needed.

• Pre‑operative reduction of salivary, respiratory and gastrointestinal secretions.
• Adjunct to anesthesia to control airway secretions and prevent bronchospasm.
• Management of acute exacerbations of chronic obstructive pulmonary disease (COPD) to improve airflow.
• Off‑label use for severe hyperhidrosis when other treatments have failed.
• Facilitation of diagnostic procedures that require minimal secretions, such as bronchoscopy.

Side effects of Glycopyrronium Bromide Ethypharm vary in frequency and severity.

Common

• Dry mouth and throat dryness.
• Urinary retention.
• Constipation.
• Blurred vision.
• Tachycardia.
• Skin flushing.

Serious

• Anaphylactic or severe allergic reaction.
• Cardiac arrhythmias.
• Severe hypotension.
• Acute angle‑closure glaucoma.
• Persistent severe urinary retention requiring catheterization.
• Respiratory distress due to bronchospasm.

Before initiating Glycopyrronium Bromide Ethypharm, clinicians should evaluate several safety considerations.

• Caution in patients with glaucoma, especially narrow‑angle type.
• Avoid use in individuals with known urinary retention or prostatic hypertrophy.
• Assess for gastrointestinal obstruction or severe constipation.
• Use carefully in patients with cardiovascular disease, arrhythmias, or uncontrolled hypertension.
• Elderly patients may be more susceptible to anticholinergic effects.
• Pregnancy and lactation status are not well established; weigh potential risks and benefits.
• Monitor for signs of excessive anticholinergic burden when combined with other agents.

Glycopyrronium Bromide Ethypharm can interact with various medications; awareness helps prevent adverse outcomes.

Avoid

• Concurrent use of other anticholinergic drugs (e.g., antihistamines, tricyclic antidepressants) that may amplify anticholinergic effects.
• Cholinesterase inhibitors (e.g., donepezil, rivastigmine) which counteract its mechanism.
• Medications that prolong the QT interval, increasing cardiac risk.

Use with caution

• Anesthetic agents and muscle relaxants that may potentiate respiratory depression.
• Beta‑agonists or other bronchodilators, as combined effects on heart rate may occur.
• Antihistamines and phenothiazines, which add to anticholinergic load.
• Opioids, due to potential additive sedation and respiratory effects.
• Monoamine oxidase inhibitors (MAOIs), requiring close monitoring.